


Appl. No. 10/606,084  
 Amdt. Dated 04/25/05  
 Reply to Office Action of 04/20/05

### Amendment to the Claims:

The following listing of claims will replace all prior versions, and listings, of claims in the application:

### Listing of Claims:

1. (Original) The compound of formula I or pharmaceutically acceptable esters, ethers, and/or salts thereof:



wherein:

Q is selected from the group consisting of -O- and -N(R)-;

R is selected from the group consisting of -H and -C<sub>1-6</sub>alkyl;

Z is selected from the group consisting of -C<sub>1-6</sub>alkyl-O- and -C<sub>1-4</sub>alkyl-cycloalkyl-O-; and

Y is selected from the group consisting of tetrazoyl, oxazoyl, thiazoyl, pyridyl, N-oxo-pyridyl, pyrimidinyl, and pyrazinyl; each valence permitting unsubstituted, mono- or polysubstituted with one or more instances selected from the group consisting of halo, -OR, -NR<sub>2</sub>, -SR, -C<sub>1-6</sub>alkyl, -CO<sub>2</sub>H, -CO<sub>2</sub>Ph, and -CO<sub>2</sub>C<sub>1-6</sub>alkyl.

2. (Original) The compound of claim 1 or pharmaceutically acceptable esters, ethers, and/or salts thereof, wherein:

Q is -N(R)-;

R is selected from the group consisting of -H and -C<sub>1-6</sub>alkyl;

Z is selected from the group consisting of -C<sub>1-6</sub>alkyl-O- and -C<sub>1-4</sub>alkyl-cycloalkyl-O-; and

Y is selected from the group consisting of tetrazoyl, oxazoyl, thiazoyl, pyridyl, N-oxo-pyridyl, pyrimidinyl, and pyrazinyl; valence permitting unsubstituted, mono- or polysubstituted with one or more instances selected from the group consisting of halo, -OR, -NR<sub>2</sub>, -SR, -C<sub>1-6</sub>alkyl, -CO<sub>2</sub>H, -CO<sub>2</sub>Ph, and -CO<sub>2</sub>C<sub>1-6</sub>alkyl.

Appl. No. 10/606,084  
Amdt. Dated 04/25/05  
Reply to Office Action of 04/20/05

3. (Original) The compound of claim 2 or pharmaceutically acceptable esters, ethers, and/or salts thereof, wherein Z is -C<sub>1-6</sub>alkyl-O-.

4. (Original) The compound of claim 3 or pharmaceutically acceptable esters, ethers, and/or salts thereof, wherein Z is -*n*-propyl-O-.

5. (Original) The compound of claim 4 or pharmaceutically acceptable esters, ethers, and/or salts thereof, wherein Y is pyridyl.

6. (Original) The compound of claim 1 or pharmaceutically acceptable esters, ethers, and/or salts thereof, wherein:

Q is O;

R is selected from the group consisting of -H and -C<sub>1-6</sub>alkyl;

Z is selected from the group consisting of -C<sub>1-6</sub>alkyl-O- and -C<sub>1-4</sub>alkyl-cycloalkyl-O-; and

Y is selected from the group consisting of tetrazoyl, oxazoyl, thiazoyl, pyridyl, N-oxo-pyridyl, pyrimidinyl, and pyrazinyl; each valence permitting unsubstituted, mono- or polysubstituted with one or more instances selected from the group consisting of halo, -OR, -NR<sub>2</sub>, -SR, -C<sub>1-6</sub>alkyl, -CO<sub>2</sub>H, -CO<sub>2</sub>Ph, and -CO<sub>2</sub>C<sub>1-6</sub>alkyl.


7. (Original) The compound of claim 6 or pharmaceutically acceptable esters, ethers, and/or salts thereof, wherein Z is -C<sub>1-6</sub>alkyl-O-.

8. (Original) The compound of claim 7 or pharmaceutically acceptable esters, ethers, and/or salts thereof, wherein Z is -*n*-propyl-O-.

9. (Original) The compound of claim 8 or pharmaceutically acceptable esters, ethers, and/or salts thereof, wherein Y is pyridyl.

Appl. No. 10/606,084  
 Amdt. Dated 04/25/05  
 Reply to Office Action of 04/20/05

10. (Original) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and as active ingredient the compound of formula I



wherein:

Q is selected from the group consisting of -O- and -N(R)-;

R is selected from the group consisting of -H and -C<sub>1-6</sub>alkyl;

Z is selected from the group consisting of -C<sub>1-6</sub>alkyl-O- and -C<sub>1-4</sub>alkyl-cycloalkyl-O-; and

Y is selected from the group consisting of tetrazoyl, oxazoyl, thiazoyl, pyridyl, N-oxo-pyridyl, pyrimidinyl, and pyrazinyl; each valence permitting unsubstituted, mono- or polysubstituted with one or more instances selected from the group consisting of halo, -OR, -NR<sub>2</sub>, -SR, -C<sub>1-6</sub>alkyl, -CO<sub>2</sub>H, -CO<sub>2</sub>Ph, and -CO<sub>2</sub>C<sub>1-6</sub>alkyl.

11. (Currently Amended) A method of treatment of ~~a cancer~~ breast cancer or lymphoma in a patient, which method comprises administering to a patient a therapeutically effective amount of the compound of claim 1.

12. (Currently Amended) A method of treatment of ~~a cancer~~ breast cancer or lymphoma in a patient, which method comprises administering to a patient a therapeutically effective amount of the composition of claim 9.

13. (Cancelled)

14. (Cancelled)

15. (Cancelled)

16. (Cancelled)

Appl. No. 10/606,084  
Amdt. Dated 04/25/05  
Reply to Office Action of 04/20/05

17. (New) The method of claim 11, wherein the lymphoma is B-cell lymphoma.

18. (New) The method of claim 12, wherein the lymphoma is B-cell lymphoma.